These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2347 related items for PubMed ID: 12670638

  • 1. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.
    Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638
    [Abstract] [Full Text] [Related]

  • 2. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C.
    Cochrane Database Syst Rev; 2019 Sep 04; 9(9):CD005049. PubMed ID: 31483500
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.
    Slavik RS, Tisdale JE, Borzak S.
    Prog Cardiovasc Dis; 2001 Sep 04; 44(2):121-52. PubMed ID: 11568824
    [Abstract] [Full Text] [Related]

  • 4. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A, Husser D, Cannom DS.
    Am J Cardiovasc Drugs; 2005 Sep 04; 5(6):371-8. PubMed ID: 16259525
    [Abstract] [Full Text] [Related]

  • 5. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM, Verma A, Talajic M, Nattel S, Dorian P, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Sep 04; 27(1):47-59. PubMed ID: 21329862
    [Abstract] [Full Text] [Related]

  • 6. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN, Mody FV, Lopez B, Sarma JS.
    Am J Cardiol; 1999 Nov 04; 84(9A):161R-173R. PubMed ID: 10568677
    [Abstract] [Full Text] [Related]

  • 7. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Bhatta L, Khan M, Hynes J, Samii S, Luck J.
    J Interv Card Electrophysiol; 2003 Oct 04; 9(2):215-22. PubMed ID: 14574034
    [Abstract] [Full Text] [Related]

  • 8. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec 04; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 9. Atrial fibrillation: rate control often better than rhythm control.
    Prescrire Int; 2004 Apr 04; 13(70):64-9. PubMed ID: 15148984
    [Abstract] [Full Text] [Related]

  • 10. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J.
    Cochrane Database Syst Rev; 2015 Mar 28; (3):CD005049. PubMed ID: 25820938
    [Abstract] [Full Text] [Related]

  • 11. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP, Cox CD.
    Pharmacotherapy; 2001 Dec 28; 21(12):1514-29. PubMed ID: 11765303
    [Abstract] [Full Text] [Related]

  • 12. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD005049. PubMed ID: 22592700
    [Abstract] [Full Text] [Related]

  • 13. Dronedarone: a promising alternative for the management of atrial fibrillation.
    Yalta K, Turgut OO, Yilmaz MB, Yilmaz A, Tandogan I.
    Cardiovasc Drugs Ther; 2009 Oct 16; 23(5):385-93. PubMed ID: 19669399
    [Abstract] [Full Text] [Related]

  • 14. Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
    Humphries KH, Kerr CR, Steinbuch M, Dorian P, Canadian Registry of Atrial Fibrillation investigators.
    CMAJ; 2004 Sep 28; 171(7):741-5. PubMed ID: 15451836
    [Abstract] [Full Text] [Related]

  • 15. Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.
    Naccarelli GV, Hynes J, Wolbrette DL, Bhatta L, Khan M, Luck J.
    Curr Cardiol Rep; 2002 Sep 28; 4(5):418-25. PubMed ID: 12169239
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
    Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D, Khattak F, Adelstein E, Jain SK, Saba S.
    J Cardiol; 2016 May 28; 67(5):471-6. PubMed ID: 26233885
    [Abstract] [Full Text] [Related]

  • 17. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation.
    Deneer VH, Borgh MB, Kingma JH, Lie-A-Huen L, Brouwers JR.
    Pharm World Sci; 2004 Apr 28; 26(2):66-78. PubMed ID: 15085940
    [Abstract] [Full Text] [Related]

  • 18. Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits.
    Camm J.
    Int J Cardiol; 2012 Mar 22; 155(3):362-71. PubMed ID: 21708411
    [Abstract] [Full Text] [Related]

  • 19. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ.
    N Engl J Med; 1999 Sep 16; 341(12):857-65. PubMed ID: 10486417
    [Abstract] [Full Text] [Related]

  • 20. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF.
    Cochrane Database Syst Rev; 2007 Oct 17; (4):CD005049. PubMed ID: 17943835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 118.